A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
| Condition | Intervention | Phase |
|---|---|---|
|
Anthrax |
Biological: AV7909 Biological: BioThrax |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers |
- Toxin Neutralizing Antibody (TNA) Level at Day 63 [ Time Frame: Day 63 ] [ Designated as safety issue: No ]Immunogenicity measured by the lower bound (LB) of the 95% confidence intervals (CIs) for the proportion of subjects in each study arm with Day 63 TNA 50% neutralization factor (NF50) values greater than or equal to threshold
- Number of Adverse Events [ Time Frame: Up to 12 months ] [ Designated as safety issue: Yes ]Safety will be evaluated by adverse events, including assessment of symptoms, physical exam findings, clinical laboratory tests, and vital signs.
- TNA Level at Day 42 [ Time Frame: Day 42 ] [ Designated as safety issue: No ]Immunogenicity measured by the percentage of subjects in each study arm with Day 42 TNA NF50 values greater than or equal to threshold
- TNA Level at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]Immunogenicity measured by the percentage of subjects with Day 28 TNA NF50 values greater than or equal to threshold
- TNA Seroconversion Rate [ Time Frame: Up to Day 84 ] [ Designated as safety issue: No ]Immunogenicity measured by the percentage of subjects who have seroconverted (defined as a 4-fold increase over Day 0 in TNA NF50 value) at Days 21, 28, 35, 42, 49, 63, and 84
| Estimated Enrollment: | 168 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: AV7909 (Day 0 and 14)
Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
|
Biological: AV7909
Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
Other Names:
|
|
Experimental: AV7909 (Day 0 and 28)
Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
|
Biological: AV7909
Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
Other Names:
|
|
Experimental: AV7909 (Day 0, 14, and 28)
Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
|
Biological: AV7909
Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
Other Names:
|
|
Experimental: AV7909 Reduced Dose
Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
|
Biological: AV7909
Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
Other Names:
|
|
Active Comparator: BioThrax
Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
|
Biological: BioThrax
Other Name: Anthrax Vaccine Adsorbed (AVA)
|
Detailed Description:
The safety and immunogenicity of AV7909 for post-exposure prophylaxis of anthrax will be evaluated using a randomized, parallel-group, active-controlled, double-blind design with three immunization schedules and two dose levels in healthy adult volunteers. Safety will be assessed by clinical laboratory tests (hematology, serum chemistry, and urinalysis), monitoring of adverse events, vital signs, and physical examinations. Reactogenicity (systemic and injection site reactions) will be assessed by the subjects using subject e-diaries for 7 days after each immunization and by the investigator at in-clinic visits 7 and 14 days after each immunization, and at other visits, if applicable. Immunogenicity will be measured as toxin neutralizing antibody (TNA) response and seroconversion rates.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be 18-50 years old
- Be in good health
- Have access to a computer and the internet so you can complete a diary
- Agree to abstain from sex the first 84 days of the study or practice birth control if you are a woman who is able to get pregnant
- Have not donated blood for the previous 8 weeks
Exclusion Criteria:
- A known anaphylactic response, severe systemic response, or serious hypersensitivity reaction to a prior immunization.
- A history of latex allergy.
- Have received a shot (vaccine), including flu shots, in the past 6 weeks or plan to get a shot for 4 weeks after the last study shot is given.
- Have previously served in the military any time after 1990 or plan to enlist in the military from Screening through Day 84.
- Prior immunization with anthrax vaccine, recombinant protective antigen (rPA) vaccine, or known exposure to anthrax organisms.
- Have participated in anthrax therapeutic or vaccine studies (monoclonal anti-PA or anthrax immune globulins or anthrax vaccines).
- Participation in any investigational study involving use of a pharmacological intervention within 30 days before the Screening visit or planning to participate in a study requiring dosing through the 12-month safety follow-up telephone call.
- Have a known diagnosis of any immunodeficiency disease including but not limited to: acquired immune deficiency syndrome (AIDS), common variable immunodeficiency disease, immunoglobulin A (IgA) deficiency, or hypogammaglobulinemia.
- Past history of significant autoimmune disease such as rheumatoid arthritis, lupus erythematous, psoriasis in the area of vaccinations, or requires immunotherapy, glomerulonephritis, or autoimmune thyroiditis.
- Have received immunosuppressive therapy with cytotoxic drugs or Rituximab within the past 2 years.
- A history of cytotoxic chemotherapy or radiation therapy.
- Chronic (>10 days) daily oral or parenteral corticosteroid therapy in the past 12 months.
- Any lung disease, including reactive airway disease, which requires the daily use of medications.
- A female currently breastfeeding or with a positive pregnancy test.
- A history of drug or alcohol abuse within 12 months prior to Screening, or a positive result on a urine drug screen for cocaine, marijuana, opiates, methamphetamines, benzodiazepines, or oxycodone.
- Any tattoo or other skin condition in the deltoid region on either arm that may obscure the assessment of the injection sites.
- A medical condition that, in the opinion of the PI or designee, could adversely impact the subject's participation or safety or the conduct of the study.
- Any planned elective in-patient surgery during the study period.
Contacts and Locations| United States, Florida | |
| Miami Research Associates | Recruiting |
| Miami, Florida, United States, 33143 | |
| Contact: Eric Sheldon, MD 305-665-5151 | |
| Contact: Terry Piedra 305-665-5151 | |
| Principal Investigator: Eric Sheldon, MD | |
| United States, South Carolina | |
| Costal Carolina Research | Recruiting |
| Mount Pleasant, South Carolina, United States, 29464 | |
| Contact: Cynthia B Strout, MD 843-856-3784 ccrc@costalcarolinaresearch.com | |
| Contact: Hana Comer 843-856-3784 ccrc@costalcarolinaresearch.com | |
| Principal Investigator: Cynthia B Strout, MD | |
| United States, Texas | |
| Central Texas Allergy and Asthma | Not yet recruiting |
| New Braunfels, Texas, United States, 78130 | |
| Contact: Frank Hampel, MD 830-609-0998 trials@ctxhr.com | |
| Contact: Kay Reneau 830-609-0998 trials@ctxhr.com | |
| Principal Investigator: Frank Hampel, MD | |
| United States, Utah | |
| Jean Brown Research | Recruiting |
| Salt Lake City, Utah, United States, 84124 | |
| Contact: Derek D Muse, MD 801-261-2000 info@jeanbrownresearch.com | |
| Contact: Carol Minoughan 801-261-2000 info@jeanbrownresearch.com | |
| Principal Investigator: Derek D Muse, MD | |
| Principal Investigator: | Robert Hopkins, MD, MPH, TM | Emergent BioSolutions |
More Information
No publications provided
| Responsible Party: | Emergent BioSolutions |
| ClinicalTrials.gov Identifier: | NCT01770743 History of Changes |
| Other Study ID Numbers: | EBS.AVA.208 / DMID 11-0055, HHSN272201000035C |
| Study First Received: | January 16, 2013 |
| Last Updated: | January 16, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Emergent BioSolutions:
|
post-exposure prophylaxis toxin neutralization assay |
Additional relevant MeSH terms:
|
Anthrax Bacillaceae Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on May 16, 2013